Remus PharmaceuticalsNSE:REMUS -1.02%55 Interest Coverage is 34.51 as of Mar. 2026, which is 2% below its 10-year median of 35.09. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 89 Medical Distribution companies, Remus Pharmaceuticals ranks better than 77.53% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Remus Pharmaceuticals's
Operating Income
for the
six
months ended in Mar. 2026 was ₹283 Mil. Remus Pharmaceuticals's Interest Expense for the
six
months ended in Mar. 2026 was ₹-8 Mil.
Remus Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 34.51.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Remus Pharmaceuticals's Interest Coverage or its related term are showing as below:
NSE:REMUS'
s Interest Coverage Range Over the Past 10 Years
Min: 25.29 Med: 35.09 Max: 55.66
Current: 36.68
NSE:REMUS's Interest Coverage is ranked better than 77.53% of 89
companies
in the Medical Distribution industry
Industry Median: 6.23
vs NSE:REMUS: 36.68
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Remus Pharmaceuticals Interest Coverage Related Terms
Remus Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:REMUS vs MCK, CAH, COR: Interest Coverage Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Interest Coverage vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a Interest Coverage of 34.51 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Remus Pharmaceuticals and its competitors. This is near median its historical median of 35.09. Over the past decade, Remus Pharmaceuticals' Interest Coverage has ranged from 25.29 to 55.66. According to the industry distribution chart, Remus Pharmaceuticals ranks #20 out of 89 companies in the Medical Distribution industry, placing it in the top 22.5%.
Is Remus Pharmaceuticals' Interest Coverage too high?
Remus Pharmaceuticals' current Interest Coverage of 34.51 is near median its 10-year median of 35.09. Over the past 10 years, this metric has ranged from a low of 25.29 to a high of 55.66. The Medical Distribution industry median Interest Coverage is 6.23. Remus Pharmaceuticals' value of 34.51 is 453.9% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #20 out of 89 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Interest Coverage compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #20 out of 89 companies for Interest Coverage. This places Remus Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 6.23. Remus Pharmaceuticals' value of 34.51 is 453.9% above this benchmark. Historically, Remus Pharmaceuticals' own Interest Coverage has ranged from 25.29 to 55.66 over the past decade. While the company's 10-year median is 35.09 vs. the industry median of 6.23, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Distribution company?
The median Interest Coverage among Medical Distribution companies is 6.23, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Interest Coverage of 34.51 is 453.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Interest Coverage is 6.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Interest Coverage is 34.51, which is near median its own 10-year median of 35.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current Interest Coverage is 34.51, which is near median its 10-year median of 35.09 and 453.9% above the Medical Distribution industry median of 6.23. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Interest Coverage is 34.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Interest Coverage: 34.51 (near median its 10-year median of 35.09)
GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
Industry Position: 453.9% above the Medical Distribution median (#20 of 89)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
